Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of JW0301 vs C2105 in Healthy Subjects
NCT05433844Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rabeprazole and sodium bicarbonate in gastroesophageal reflux disease (GERD), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area under the plasma drug concentration-time curve within a dosing interval at steady state and Percent decrease from baseline in integrated gastric acidity at 7 days. Started Jun 2022; status: completed.
02
Drugs
rabeprazolesodium bicarbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05433844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433844.